We are live on
!
Find out more
ALXN
Alexion Pharmaceuticals
ALXN
ALXN
Delisted
ALXN was delisted on the 20th of July, 2021.
646 hedge funds and large institutions have $20.1B invested in Alexion Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 246 increasing their positions, 226 reducing their positions, and 80 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
15% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 80
2% more funds holding
Funds holding: 636 → 646 (+10)
9% more repeat investments, than reductions
Existing positions increased: 246 | Existing positions reduced: 226
28% less capital invested
Capital invested by funds: $27.9B → $20.1B (-$7.74B)
36% less call options, than puts
Call options by funds: $176M | Put options by funds: $275M
Holders
646
Holders Change
+10
Holders Change %
+1.57%
% of All Funds
14.17%
Holding in Top 10
16
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+33.33%
% of All Funds
0.35%
New
92
Increased
246
Reduced
226
Closed
80
Calls
$176M
Puts
$275M
Net Calls
-$98.9M
Net Calls Change
-$97M
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$192M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$184M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$163M |
| 4 |
D.E. Shaw & Co
New York
|
+$155M |
| 5 |
Ninety One (UK)
London,
United Kingdom
|
+$153M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$786M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$675M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$272M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$249M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$112M |
